• Home
  • NEW DAY MEDICINE
  • 4 (90) 2026
  • 83 -4 (90) 2026 - Duschanova Z.A., Saparbayeva N.R. - NEUROENDOCRINE AND METABOLIC APPROACHES TO THE MANAGEMENT OF POLYCYSTIC OVARY SYNDROME: A LITERATURE REVIEW

83 -4 (90) 2026 - Duschanova Z.A., Saparbayeva N.R. - NEUROENDOCRINE AND METABOLIC APPROACHES TO THE MANAGEMENT OF POLYCYSTIC OVARY SYNDROME: A LITERATURE REVIEW

NEUROENDOCRINE AND METABOLIC APPROACHES TO THE MANAGEMENT OF POLYCYSTIC OVARY SYNDROME: A LITERATURE REVIEW

Duschanova Z.A. - Urgench State Medical Institute

Saparbayeva N.R. - Urgench State Medical Institute

Rajabova G.O. - Urgench State Medical Institute

Resume

Background: Polycystic ovary syndrome (PCOS) is a complex systemic disorder characterized by significant neuroendocrine and metabolic imbalances. The KNDy neuron system (kisspeptin/neurokinin B/dynorphin) plays a pivotal role in the central pathogenesis of PCOS by regulating GnRH pulsatility. Objective: To synthesize current evidence regarding the role of the KNDy system in PCOS and to emphasize the importance of conservative therapeutic strategies targeting neuroendocrine and metabolic pathways. Methods: A comprehensive literature review was performed using PubMed and Scopus databases for the period 2021–2026, focusing on central regulatory mechanisms and insulin resistance. Results: Evidence suggests that KNDy neuron hyperactivity leads to accelerated GnRH pulses and subsequent LH hypersecretion. Conservative management, incorporating insulin sensitizers and emerging neuroendocrine modulators, proves essential for metabolic and reproductive restoration. Conclusion: Understanding KNDy receptor dynamics provides a basis for novel pharmacological interventions, favoring personalized conservative treatment over invasive methods.

Keywords: Polycystic ovary syndrome (PCOS), KNDy neurons, kisspeptin, neurokinin B, hypothalamo-pituitary axis, insulin resistance, conservative management, metabolic dysfunction.

First page

546

Last page

554

For citation:Duschanova Z.A., Saparbayeva N.R., Rajabova G.O. - NEUROENDOCRINE AND METABOLIC APPROACHES TO THE MANAGEMENT OF POLYCYSTIC OVARY SYNDROME: A LITERATURE REVIEW//New Day in Medicine 4(90)2026 546-554 https://newdayworldmedicine.com/en/new_day_medicine/4-90-2026

List of References

  1. Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2023;120(4):767-793. doi:10.1016/j.fertnstert.2023.07.025.
  2. Azziz R. Polycystic ovary syndrome. Obstet Gynecol. 2018;132(2):321-336.
  3. Stener-Victorin E, Deng Q. Neuroendocrine and metabolic dysregulation in PCOS. Nat Rev Endocrinol. 2021;17:521-533. doi:10.1038/s41574-021-00517-x.
  4. Moore AM, Campbell RE. The neuroendocrine KNDy network: the heart of reproduction. Front Endocrinol (Lausanne). 2022;13:832534.
  5. Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited. Endocr Rev. 2021;42(6):754-768.
  6. Abbara A, Eng PC, Phylactou M, et al. Neurokinin B receptor antagonism for the treatment of PCOS. J Clin Endocrinol Metab. 2025;110(1):15-28.
  7. Plant TM. The neuroendocrine control of gonadotropin secretion. Endocrinology. 2019;160(10):2376-2384.
  8. Skorupskaite K, George JT, Anderson RA. The KNDy pathway as a therapeutic target in women with polycystic ovary syndrome. Hum Reprod Update. 2022;28(3):321-334.
  9. McCartney CR, Marshall JC. Polycystic ovary syndrome. N Engl J Med. 2021;375(1):54-64.
  10. Silveira MA, Moore AM. Role of androgen receptor signaling in the PCOS neuroendocrine phenotype. J Endocrinol. 2024;261(2):R15-R29.

    file

    download